Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
Acadia's Phase 2 RADIANT topline results enable Phase 3 for remlifanserin in Alzheimer's psychosis.
What changed
Acadia's Phase 2 RADIANT topline results enable Phase 3 for remlifanserin in Alzheimer's psychosis.
Why it matters
Acadia's Phase 2 RADIANT topline results enable Phase 3 for remlifanserin in Alzheimer's psychosis. — impact context not separately stored; see What changed.
← Dashboard
Sep 25, 2026 06:21 AM ET